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Abstract
Serotonin (5-hydroxytryptamine; 5-HT) is a crucial biological signaling molecule involved in a variety of
physiological processes and has been shown to play a critical role in gut functions including secretion,
motility and sending signals to the central nervous system. Alterations in 5-HT signaling and metabolism
have been implicated in gut dysfunction associated with gastrointestinal (GI) disorders, such as irritable
bowel syndrome (IBS). It is widely recognized that 5-HT is either recycled via serotonin transporter
(SERT) or enzymatically degraded by monoamine oxidase (MAO-A & MAO-B). However, several enzymes thought to be involved in the breakdown of serotonin are less well-studied. Depending on the enzymes involved in 5-HT breakdown, certain active metabolites are produced that may contribute to the
role of 5-HT on gut motility. Thus, the aim of the current study is to investigate the expression and distribution of enzymes that degrade serotonin across the GI tract with the focus of contributing to scientific
knowledge centered around the development of new therapeutic approaches to address IBS symptomatology. In order to explore the gap in understanding of 5-HT-degrading enzyme distribution in the GI tract,
full-thickness tissue sections (stomach, duodenum, jejunum, ileum, cecum, proximal colon, distal colon)
were collected from male B6 mice. cDNA was generated by reverse transcriptase reactions following
RNA extraction of the collected tissue. Levels of expression of proteins of interest (MAO-A; MAO-B;
IDO; NAT-2; AR; ALDH1, TPH1, SERT) were measured using quantitative PCR (qPCR). q-PCR was
also conducted on pooled human RNA samples (stomach, small intestine, colon). The results demonstrate
detectable levels of all of the enzymes included in this study. Across the mouse GI tissues, higher levels of
expression of SERT, MAO-B, IDO and NAT-2 in the proximal intestine, whereas, MAO-A and TPH1
demonstrated higher levels of expression in the colon. MAO-A showed the largest levels of expression
overall, followed by SERT and tryptophan hydroxylase (TPH1). ALDH and AR showed minimal level of
expression overall across all tissues. Additionally, a comparison of trends across mouse GI tissues shows
a relatively similar distribution to that in humans. However, SERT and MAO-B showed a different trend
between humans and mice. The results also demonstrate considerable variation across samples, especially
in the colon. The demonstrated within-tissue variation of expression suggests that further consideration of
how small intestine and large intestine samples are identified and collected is important when considering
enzymatic activity and targets for GI-based disorders. In order to strengthen the results, future experimentation may include increasing the sample size for greater statistical analysis.

Keywords: Serotonin, motility, SERT, MAO-A, gastrointestinal tract, IBS, TPH1, RT-PCR, q-PCR
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Introduction
Serotonin (5-hydroxytryptamine; 5-HT) is a crucial biological signaling molecule, derived from the essential amino acid L-tryptophan, that has extensive intercellular signaling actions throughout the body (Mawe and Hoffman 2013; Spohn and Mawe, 2017). It was first discovered in the gastrointestinal tract (GI), where it influences secretion, motility and immune
function (Vialli & Erspamer, 1937, as reviewed in Mawe and Hoffman 2013). However, 5-HT is
most widely associated with the central nervous system (CNS) based on research involving its
pervasive modulatory effect on mood and behavior. Extensive research has been conducted to
elucidate the functions of 5-HT in the brain, but many of the precise mechanisms through which
it acts have yet to be established. Moreover, the vast assortment of proteins involved in 5-HT action adds to the complexity and difficulty of understanding 5-HT function. Furthermore, the exact role of 5-HT is complicated by its widespread regulatory functions in the periphery, including
hematopoiesis, metabolism maintenance and neuroprotection (as reviewed in Spohn and Mawe,
2017). Currently, 5-HT is implicated in a wide variety of physiological conditions and regulatory
systems in both the CNS and PNS (Berger, Gray & Roth, 2009).
Within the GI tract, 5-HT is known to play critical roles in gut function and sensation,
and alterations in 5-HT signaling and metabolism have been implicated in gut dysfunction
(Mawe & Hoffman, 2013). According to previous research, the vast majority of 5-HT found in the body
resides in the gut with more than 90% found in the intestinal mucosa, a protective barrier of cells that separate intestinal microbes from the rest of the body.
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Within the GI tract, 5-HT is largely found in enterochromaffin cells (EC), neuroendocrine cells
located in the intestinal epithelium (as reviewed in Keszthelyi et. al., 2009). EC cells use tryptophan hydroxylase 1 (TPH1) to synthesize and secrete 5-HT for later reuptake or catabolism.
When released, 5-HT acts on receptors within the submucosal and myenteric plexuses. Increased
expression of EC cells, and thus increased production of 5-HT, has been implicated in ulcerative
colitis (UC) and Crohn's disease (Terry & Margolis, 2017). It is worth noting that this mechanism is distinct from neuronal 5-HT in which a different variant, TPH2, is responsible for synthesis (McKinney, Knappskog & Haavik, 2015).
The activity of 5-HT is terminated by serotonin uptake involving the serotonin-selective
reuptake transporter (SERT). SERT is a sodium-dependent transporter that terminates the actions
of 5-HT via reuptake, thus serving as a regulatory mechanism for the available levels of 5-HT in
the gut. Due to the sensitivity of 5-HT, rapid uptake is crucial to the function of 5-HT. In a study
investigating altered 5-HT signaling in patients with irritable bowel syndrome (IBS) or ulcerative
colitis (UC), the Mawe lab showed reduced 5-HT transporter expression leading to increased
availability of mucosal 5-HT (Coates et al., 2004). A lower expression of the transporter could
have implications on gut function and sensitivity as demonstrated in a related study investigating
the effect of SERT inhibition that showed an altered visceromotor response, reduced upper GI
transit, and delayed defecation frequency. A reduction in SERT expression would translate to an
increased level of 5-HT in (enteric) neuronal synapses. The findings support the
general claim that 5-HT is a crucial molecule involved in GI function (Coates,
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Johnson, Greenwood & Mawe, 2006). So, while SERT is not a degradative enzyme it is an important component of the overall process of 5-HT catabolism. Also, since it has been previously
investigated, it is included in the current study as a comparative measure.
Most of the critical elements of mucosal 5-HT signaling, including synthesis, storage,
release, receptor activation and reuptake are fairly well understood, but the mechanisms of 5-HT
catabolism represent a gap in common knowledge. In the central nervous system, neuronal 5-HT
is broken down by monoamine oxidase (MAO), which is a mitochondrial enzyme that inactivates
monoamines once they are transported from the synaptic cleft into the nerve terminal cytoplasm.
There are two variants, MAO-A and MAO-B, with MAO-A considered to have a higher affinity
for 5-HT and MAO-B having a higher affinity for catecholamines (Keszthelyi et. al., 2009).
While the breakdown of 5-HT via MAO to form 5-hydroxyindoleacetic acid (5-HIAA) is the
most studied enzymatic pathway, there are other relevant tryptophan-related metabolic pathways
that could be involved in intestinal 5-HT catabolism. These pathways include the degradation of
5-HT by indoleamine 2,3-dioxygenase (IDO) and N-acetyltransferase (NAT), which are involved
in the kynurenine and melatonin pathways, respectively. Previous research has demonstrated
considerable expression of IDO in the gut, and the kynurenine pathway is suggested to also be
implicated in gut function (Keszthelyi et. al., 2009), but the distributions and functions of these
enzymes have not been thoroughly investigated. Nevertheless, this is a relevant issue because
metabolites formed along these pathways are bioactive.
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(from Keszthelyi et. al., 2009)

While a comprehensive investigation of the regional expression of 5-HT degradative enzymes has not been previously conducted along the gut tube, expression of several of these proteins have been reported in the GI tract. Based on preceding studies, it has since been established
that SERT expression is highest in the small intestine with lower expression in the colon. It has
also been shown that human SERT expression is largely dependent on the segment of the small
intestine investigated, due to considerable variation across regions (Gill et al. 2008). Previous
research investigating the expression of IDO has also shown a higher level of expression within
the small intestine compared to the colon, in the mouse (Dai & Zhu, 2010). An investigation of
the expression of NAT-2 across several different animal models found that NAT-2 was expressed
highest in the cecum of the mouse model with a notable reduction in expression from proximal to
distal colon. It was also noted that NAT expression (variants 1 & 2) differed significantly between the models used (Ware & Svenson, 1996). While MAO has been studied within the GI
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tract, there is a lack of data on the distribution across tissues (Mustala, Solatunturi & Tarpila,
1969).
Considering the widespread action of 5-HT in the GI tract, it is important to understand
the 5-HT degradative mechanisms that influence both normal and disease-states. A heightened
level of 5-HT availability has been shown to underlie inflammation related to GI disorders
(Mawe & Hoffman, 2013). Certain proteins of interest have since been implicated in diseasestates, but have not been significantly studied. SERT expression has been demonstrated to be
suppressed in inflammatory conditions and is likely one of the mechanisms that underlie inflammation (Terry & Margolis, 2017). Additionally, the kynurenine pathway, while not extensively studied, has also been implicated in states of inflammation on the basis of T-cell suppression. Thus, IDO expression has been shown at elevated levels among patients with irritable bowel disease (IBD) and celiac disease as a means of an anti-inflammatory response (Keszthelyi et.
al., 2009).
Due to the extensive activity of 5-HT, homeostatic regulation is incredibly important for
normal functioning of many processes in the periphery and the breakdown of 5-HT is a key determinant in regulation. Thus, it is important to understand 5-HT catabolism in order to comprehend the regulation of 5-HT as a whole. A stronger understanding of 5-HT degradation in the gut
is important due to the established link between 5-HT and altered motility, specifically IBS. Approximately 10% of the worldwide adult population suffers from IBS, which is a chronic condition affecting the large intestine and is characterized by debilitating gastrointestinal symptoms
(Holtmann, Ford & Talley, 2016). While many treatments exist that target symptoms associated
with IBS, the effectiveness is often limited to a small portion of patients. Due to the significant
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role of 5-HT in normal gut function, there is a class of medications called prokinetic agents that
are 5-HT4 receptor agonists. As an agonist, these medications serve to activate the 5-HT receptor
in order to produce a response. Unfortunately, medications within this class have been pulled
from the market or are otherwise unavailable due to significant cardiac interactions, a severe unexpected side effect (Portalatin & Winstead, 2012). Further identification of the enzymatic machinery involved in 5-HT catabolism and its distribution across tissues, as well as subsequent
metabolite production, would provide new options for future medications. A better understanding
of 5-HT metabolism is crucial to the development of new therapeutic approaches to addressing
IBS symptomatology and other gastrointestinal dysfunctions.
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Methods
This project involved the use of shared tissue from mice that were being used for studies in the
Mawe Laboratory approved under IACUC protocol #17-025. Human samples were purchased
from ThermoFisher Scientific at a concentration of 1ug/ul. Samples were collected according to
the manufacturer's protocol.
Tissue Collection
Full thickness tissue was collected from healthy, untreated male B6 mice with an age between 8-12 weeks (n = 5). Euthanasia was performed via CO₂ inhalation and cervical dislocation. Intact GI tracts were collected from the junction of the esophagus and stomach and at the
base of the distal colon (rectum). Gastrointestinal tissues were placed in a Krebs solution prior to
individual tissue collection. A ½ cm section of tissue was collected from the tissue sections of
interest: stomach, duodenum, jejunum, ileum, cecum, proximal colon, distal colon. Tubular
structures were sliced longitudinally in order to expose the mucosa before being collected into
tubes. Pouch-like structures (stomach, cecum) were cleared of luminal debris and cut into a ½ cm
section. Tissue sections were collected in matrix-D tubes and flash frozen in liquid nitrogen.
Frozen sections were stored at -80℃. Additionally, human total RNA samples (stomach, small
intestine, colon) were obtained from Thermo Fisher.
RNA Extraction
RNA was extracted from the collected tissue samples via Qiagen RNeasy Mini Kit. Buffers from the kit were used in addition to ethanol. RLT buffer was added to matrix-D tubes and
collected tissue was lysed using a FastPrep homogenizer. Tissue was homogenized at a speed of
6m/s for 30 seconds, four times. Tissue was placed on ice between spins. Post-extraction RNA
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quantification and quality were measured using Nanodrop and a 2ul sample. Eluted RNA was
stored at -80℃. Samples were diluted with nuclease-free water to 25ul with a 2ug/10ul concentration.
RT-qPCR
Mouse and human cDNA was generated from the diluted RNA via reverse transcription
(RT), a scientific procedure to form and amplify cDNA. cDNA was diluted with nuclease-free
water to a 1:20 ratio. RT was conducted on the human samples at a 1:10 ratio. Quantitative PCR
(q-PCR) was then used to assess the expression of 5-HT degradative enzymes, 5-HT transporter
(SERT; SLC6A4), and tryptophan hydroxylase (TPH1) across GI tissues. HPRT was used as a
house-keeping gene to standardize results. The degradative enzymes of interest included
monoamine oxidase (variants A & B; MAO-A, MAO-B), indoleamine-2,3-dioxygenase (IDO),
arylalkylamine N-acetyltransferase (NAT-2), aldehyde dehydrogenase (ALDH1) and aldose reductase (AR). Primer sets for enzymes were pre-validated through gel electrophoresis.
Enzyme Identification

Forward Sequence

Reverse Sequence

Reference

mMAO-A

5′-CAA GCA AGA CAT GCT GAG GAA3′

5′-ATA AGC AAA TTC TCG AGC AGT-3′;

(Zhang, Lei & Zhang
2011)

mMAO-B

5′-AAG ATT CCA GAA GAT GAA ATT-3′

5′-GTG GTC AAT CCA AAC AGC TTT-3′;

(Zhang, Lei & Zhang
2011)

mIDO

5′- CCT GGT TTT GAG GTT TTC GTG
TA -3′

5′- AAG GTT TCA GCA TTA AGA AGG TTG
-3

(Pan et al. 2019)

mALDH

5' - GACTTGAAGATTCAACATACC - 3'

5' - TCACAGCTTTGTCAACATCA - 3'

(Moto et al. 2005)

mAR

5′-CTCAGGGAACGTGATACCTA- 3′;

5′-TGTTTGGCACAGCTCATCAAG-3′

(Vikramadithyan et al.
2005)

mNAT2

5'- AACCTGGTACTTGGACCAAATCAG
-3'

5' - CCTAGCACACATCAACATGACCAC - 3'

(Sugamori et al. 2003)
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Table 1: Primer sequences for each of the enzymes of interest in the mouse model. Sequences were sourced from
previous studies as indicated.

Enzyme
Identification

Forward Sequence

Reverse Sequence

Reference

hMAOA

5′-AGG ACT ATC TGC TGC CAA
AC-3′

5′-AAG CTC CAC CAA CAT CTA
CG-3′;

(Duicu et al., 2016)

hMAOB

5′-GAA GAG TGG GAC AAC ATG AC
-3′

5′-CTC CAC ACT GCT TCA CAT AC-3′;

(Duicu et al., 2016)

hIDO

5′- GTGTTTCACCAAATCCACGA -3′

5′- CTGATAGCTGGGGGTTGC -3

(Arandi, Ramzi, Safaei & Monabati,
2018)

hALDH

5' - CGTTGGTTATGCTCATTTGGAAGA - 3'

5' - CTTTTGATCACGTCATCTAAAGAT
- 3'

(Pei, Reins & McDermott, 2006)

hAR

5′-GAAGGAATTTTTCCCATTGG- 3′;

5′-GACTGGCAGTACTGGATTAA-3′

(Vikramadithyan et al., 2005)

hNAT2

5'- TGACGGCAGGAATTACATTGTC 3'

5' - ACACAAGGGTTTATTTTGTTCC 3'

(Suzuki, Muroishi, Nakanishi & Oda,
2004)

Table 2: Primer sequences for each of the enzymes of interest in humans. Sequences were sourced from previous
studies as indicated.

cDNA transcripts were amplified using an Applied Biosystems 7500 Fast Real Time PCR. qPCR samples were prepared with 16 ul primer mix (Luna/TaqMan, H₂O, primer[s]) and 4ul of
diluted cDNA in a 96-well plate. Samples were amplified using the Standard 7500 mode for 45
cycles at 60-62°C, followed by a dissociation stage. A standard dilution curve based on known
concentrations was included with all runs, and each sample was run in duplicate.
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Statistical Analysis
GraphPad Prism 8 (GraphPad Software, San Diego, CA) was utilized to evaluate the data
collected from qPCR. Values for duplicate samples were averaged and then divided by the calculated concentration of HPRT across samples. Data points for each individual mouse were further
standardized based on expression levels of the stomach. Thus, data for RNA expression was divided by the expression of HPRT and then by the expression detected at the stomach level for the
mouse tissues. Outliers were taken out of the data set using Q test. Data was graphed to include
standard error between data points. A one-way ANOVA was conducted with Tukey’s test as a
post-hoc evaluation. Mean (m) and standard error (SE) was calculated for each set of data points
per GI tissue.
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Results
Mouse Samples
Higher levels of expression of SERT, MAO-B, IDO and NAT-2 were demonstrated in the
proximal intestine, compared to the colon (Figures 1A, D-F). MAO-A and TPH1 demonstrated
higher levels of expression in the colon, compared to the small intestine (Figures 1B, C). ALDH
and AR showed minimal level of expression overall across all tissues. MAO-A and SERT
showed the highest scale of expression (Figures 1A, D). Several statistically significant comparisons were made based on tissue-specific expression. The expression of TPH1 in the proximal
colon was significantly different from expression in the stomach, jejunum and ileum. The expression of MAO-A in the cecum was significantly greater than levels in the stomach and all sections (duodenum, jejunum, ileum) of the small intestine. MAO-B expression in the jejunum was
significantly greater than the expression levels of the duodenum and proximal colon. NAT-2 expression was statistically more significant in the duodenum than any of the other gastrointestinal
tissues studied. Overall, considerable variation was detected across samples, especially among
the proximal and distal segments of the colon. Importantly, sample size was reduced to an n-value of four since one mouse was omitted due to inconsistent data points that were statistical outliers.
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!
Figure 1 (A-H). Expression of target 5-HT-degradative enzymes across GI tissues in the mouse. Expression was normalized using HPRT as a housekeeping gene. All samples were standardized to stomach expression. Error bars represent standard error. N = 4.
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Human Samples
qPCR data demonstrated higher levels of expression of IDO and NAT-2 in the proximal
intestine, compared to the colon (Figure 2: E, F). MAO-A, MAO-B, SERT and TPH1 demonstrated higher levels of expression in the colon, compared to the proximal intestine (Figure 2: AD). Overall, considerable variation was demonstrated across samples, especially among the proximal and distal segments of the colon.

!
Comparison
A comparison of trends across mouse GI tissues reveals a relatively similar distribution of the
enzymes across the GI tract in humans. However, SERT and MAO-B were shown to have a different
trend between humans and mice. In the human samples, SERT and MAO-B demonstrated significantly
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higher expression in the colon whereas the mouse samples demonstrate slightly higher expression of
MAO-B in the small intestine and significantly higher expression of SERT in the small intestine. It is important to note that the human samples were not standardized to the stomach, whereas the mouse samples
were.

Discussion
The results of the current study, while exploratory in nature, support the general assumption of the presence and varied distribution of the investigated 5-HT degradation-related proteins.
The detection of the target RNA within the tested gastrointestinal tissues demonstrates the potential action of these enzymes in the breakdown of 5-HT found within enterochromaffin cells. Additionally, the variation in expression suggests potential differences in tissue function in disease
states and different targets to be considered when developing treatments for altered GI function.
Significance for several of the tissues sections for particular enzymes indicates potential
between-tissue trends. Most notably was the significance of NAT-2 in the duodenum, compared
to other tissue regions. NAT-2 levels in the duodenum was significant when compared to levels
of expression for all other tissue sections tested, demonstrating the most significant expression
overall. Other proteins tested show some significance with other tissues, including TPH1, MAOA and MAO-B. While the significance suggests trends, due to variability, there is a lack of statistical power for the data. The degree of variability for tissue sections could be a result of the low
N-value and could be evaluated further by increasing the sample size. Some other potential contributing factors for variability could be a result of different tissue collection as well as experience. Tissue was collected from mice at two different time-points (N=2; N=3) from different
cages. While all mice were mature, there was also some variation in the ages of the mice. Experience also could contribute to some of the variability. Due to the instability of RNA at room
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temperature, efficient dissection is really important. Collection at later time points may have
been more efficient as a result of skill development.
The comparison between mouse and human samples demonstrate both similarities and
differences between the distributive expression of 5-HT catabolic enzymes and related proteins.
Notably, the mouse tissues were standardized to the stomach, whereas the human tissues were
not based on the difference in individual (mouse) versus pooled data (human). The difference in
standardization may not reflect an accurate comparison of data points. However, based on the
data as it was analyzed, the comparative distribution suggests that the mouse model may accurately represent the GI functionality of humans, but more research may be needed to develop a
stronger conclusion. Further developing a comparative review of the mouse model for the purposes of GI-related studies is important due to potential variation in expression. The mouse model is largely used for gastrointestinal-based studies due to anatomical similarities, but research on
the mechanistic comparison seems to be limited.
In terms of differences in localized expression, the most notable variation detected was
the difference in expression of MAO, which is considered to be the primary degradative enzyme
for 5-HT and IDO, which is considered to be implicated in disease states. The higher levels of
expression suggested for MAO in the distal-most structures versus IDO in the proximal most
section of the small intestine suggest different localization of targets. In order to better understand the direct mechanisms and location of degradation within the epithelial cells, further experimentation is necessary to isolate the intestinal mucosa. This is an important consideration due to
the fact that neurons within the enteric system also express 5-HT and degradative enzymes
(Mawe and Hoffman, 2013).
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The most notable difference between human and mouse samples was the distribution of
SERT. Previous research investigating the distribution of SERT within the human GI tract has
shown higher levels of SERT in the small intestine with minimal expression in the colon. In a
study by Gill et al. (2008), SERT was shown to be expressed most highly in the ileum through
RT-PCR, immunostaining, as well as immunoblotting. It is worth noting that in the current study
the level of expression detected between small intestine segments in the mouse (duodenum, jejunum, ileum) drastically varied. The inter-intestinal variation is an important consideration
when analyzing data from this study. For SERT in particular, in the mouse model, there was significant variation in the data points for jejunum. This could demonstrate that expression is largely
dependent on which section is selected as a particular small intestinal region. It also demonstrates that it could be largely inaccurate to classify the small intestine as a single entity for the
purpose of elemental analysis. The large variation suggests a need to consider all regions of the
small intestine. The lack of further classification of the human small intestine total RNA sample
could be a reason for discrepancy between existing literature and the current study. The human
RNA samples used within this study were ordered from Thermo Fisher with limited source and
collection information, with the exception that samples were taken from a pool of individuals.
Additionally, depending on which segment was collected, the enzyme distribution could be altered.
Future Experimentation
As discussed previously, there are several future directions to undertake in order to develop a more holistic presentation of the distribution and functionality of enzymes within the GI
tract. Immunohistochemical (IHC) staining of intact GI tissues would provide a better localiza-
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tion as well as verification of the enzymes and proteins of interest. IHC refers to a scientific procedure that allows for the visualization of the locations of proteins, in this case enzymes, within a
tissue sample using a microscope. Additionally, high pressure liquid chromatography (HPLC)
analysis of present metabolites would also indicate the actual functionality of the enzymes.
HPLC is a sensitive technique used to separate particles based on their reaction to the absorbent
using high levels of pressure. The presence of a substance in focus is quantified by analyzing the
area under the peaks which constitute the output. This procedure would provide a better indication of the actual functionality of the enzymes involved in the catabolism of 5-HT. From experimentation, verification of a pathway(s) underlying 5-HT breakdown in the gut would be expected to be identified. This procedure would be especially important for the analysis of IDO. The
primary substrate for IDO is actually tryptophan, but it can also catabolize 5-HT (as well as 5HTP and tryptamine). In this case, knowing the metabolites would better elucidate the functionality of IDO as a potential 5-HT degradative enzyme (Keszthelyi et. al., 2009).
In order to validate the existing data, it would also be imperative to look at a larger sample size in order to have more data points for each protein at each tissue section. Due to time and
extraction quality constraints, 5 mice were utilized for data collection. However, one mouse was
omitted due to inconsistent data points that were statistical outliers. Higher n-values would allow
for statistical analysis and stronger distributive trends, especially considering the variation that
was demonstrated between samples.
Another option to more accurately understand the expression and degradative function of
5-HT catabolic enzymes in humans would be to use Caco-2 cells. Caco-2 is a human colonic
adenocarcinoma cell line that can be grown in culture and harvested for experimentation (Sam-
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buy et al., 2004). Using the same procedures as above, the investigation of enzyme presence can
be determined by evaluating what byproducts are detectable in the medium after treatment of
cultures with 5-HT. This has the advantage over mouse tissue because it is a bacteria-free preparation, and bacteria are known to express enzymes that can catabolize 5-HT. However, there are
several downsides to using Caco-2 cells as a method for experimentation. Inconsistencies may
arise due to the variation in maintenance and experimentation involving cells. Additionally, the
cellular composition of Caco-2 cells may not reflect adult intestinal tissue (Sambuy et al., 2004).
As mentioned, future experimentation aimed at isolating the intestinal mucosa in order to
restrict analysis to the enteroendocrine cell-derived 5-HT, which is the aim of this research
project, is important to understand 5-HT breakdown as it relates specifically to GI function. Isolation of the intestinal mucosa could be conducted by opening up the tissues of interest via a longitudinal slice and scraping the mucosa away from the muscularis. Through direct collection of
mucosa or pipetting from the collection dish, the existing procedure can be reproduced to investigate the expression of enzymes within just the epithelial layer.
In order to better understand the degradative function of the investigated enzymes it is
crucial to further consider the effect of inflammation and how that may affect the distribution and
overall expression levels of various enzymes. Future experimentation could induce inflammation
chemically via dextran sulfate sodium (DSS) or 2,4,6-trinitrobenzene sulfonic acid (TNBS) and
maintain the experimental methodology and data analysis. The results from this study compared
to those of an inflammation study could demonstrate how the degradation of 5-HT is affected in
GI related disorders such as IBS, IBD, UC, or Crohn’s disease (CD) based on changes in distributive expression.
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Another important aspect to consider when investigating the underlying mechanisms that
affect the normal state of functioning for the aim of developing better treatment options is to
consider sex differences. While it depends on the cultural context, in the U.S. twice as many females are treated for IBS than for males. Additionally, symptoms may vary depending on sex,
although the criteria for diagnosis is the same regardless of background factors (Camilleri, 2020).
Many factors could play a role in apparent sex differences. One of the factors may be different
mechanisms of 5-HT signaling and degradation.
Due to the variation of data points within tissues, further experimentation may better elucidate trends across the small intestine and/or colon. Data points for the proximal and distal
colon were notably varied, thus experimentation involving further segmentation of the colon may
better demonstrate the overall distributive trend of the proteins of interest. The existing procedure could be modified to collect tissue at 2 cm increments along the large intestine in order to
capture the expression of enzymes at smaller intervals. The use of multiple segments at set intervals of the colon would limit variability of collection. Some of the proximal samples may have
been collected closer to the cecum, which could have affected the data collected. The distal samples were taken from the distal-most portion of the colon, however, depending on how closely
the section was cut could have been closer to the rectum. It is worth noting that while the colon is
traditionally subdivided into the proximal and distal colon, due to the diverse functionality it may
be worth considering further divisions.
Conclusion
Overall this study demonstrates promising comparisons of the distribution of serotonin
degrading enzymes between the human GI tract and that of the mouse model. Most of the data
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suggest trends across tissue in a way that is consistent with previous research. Some unexpected
results, as well as considerable variation between expression data, suggest repeat experimentation with more samples. Additionally, there are several extensions of the current procedure that
would provide a more specific evaluation of the overall catabolism of 5-HT. The aim of the current study is to close the gap in knowledge about the mechanisms that underlie the breakdown of
5-HT. Due to the lack of research aimed at understanding the mechanistic functioning of 5-HT in
the periphery, catabolism is not considered when treatments are developed for GI-related diseases and disorders. The ideology behind the current study, combined with future experimentation, suggests that a comprehensive understanding of the enzymatic components and alterations
in expression that underlie inflammatory disease states to be vital in new drug targets. New targets would include catabolic pathways as well as localization based on distributive expression of
key enzymes of interest.
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Additional Figure(s)

!
Figure 3. Mean and standard error calculations for each GI tissue.
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